Skip to content
TheKalshiAcademy
EN

Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Markets

  • Before Jan 1, 2028

    • Yes73%
    • No27%

    Volume $1.2K · Liquidity $342.3

  • Before Oct 1, 2027

    • Yes69%
    • No31%

    Volume $872.6 · Liquidity $302.7

  • Before Jul 1, 2027

    • Yes9%
    • No91%

    Volume $36.7 · Liquidity $28.4

  • Before Apr 1, 2027

    • Yes4%
    • No96%

    Volume $0 · Liquidity $0

  • Before Jul 1, 2028

    • Yes95%
    • No5%

    Volume $0 · Liquidity $0

Resolution rules

If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Apr 1, 2027, then the market resolves to Yes.

How to read these odds

Each price runs from $0 to $1 and can be read as the probability the market assigns to an outcome: $0.62 means roughly 62%. Prices move with every trade, so they are a crowd estimate, not a guarantee. Before trading, check the resolution rules above, the volume and the liquidity, and only risk money you can afford to lose.

Probability calculators · Glossary · Free courses

More Tech & Science markets